Search Images Maps Play YouTube News Gmail Drive More »
Settings | Sign in

Avastin

Varanasi: Blinded patients were given Avastin despite alert

Hindustan Times - ‎Feb 1, 2016‎
The Drug Controller General (India) issued an alert on January 21 this year, asking the drug controllers in the states and union territories to monitor the movement of Avastin and its use in ophthalmology. (Shutterstock photo) ...

Despite, drug organisation warning, MP govt fails to check Avastin use

Hindustan Times - ‎Jan 31, 2016‎
HT had earlier reported that even though doctors around the globe use Avastin to treat vision loss, it has not been approved by the US Food and Drug Administration for the purpose.
See realtime coverage

Tanta ophthalmology hospital chief referred to investigation, Avastin importing company closed

Egypt Independent - ‎Feb 8, 2016‎
Health Minister Ahmed Emad Eddine decided on Monday to close the company that imports the Avastin medicine, which caused complications for patients who then went blind after being treated by the Tanta ophthalmology hospital.

MP hospital joins 'banwagon,' stops use of Avastin eye drug

Hindustan Times - ‎Jan 27, 2016‎
A well-known hospital in Madhya Pradesh that conducts over 1,20,000 eye procedures annually said on Monday it had stopped the use of the Avastin drug that slows the growth of new blood vessels after patients complained of swelling, pain and watery eyes.

Off-Label Use of Drugs and Access to Medicines for All: A Thailand Example

Council on Foreign Relations (blog) - ‎4 hours ago‎
A worker makes his way on a bridge at Swiss pharmaceutical company Roche plant. Roche is the manufacturer of Avastin, a cancer medication used for off-label treatment for macular disease in place of the more expensive Lucentis.
See realtime coverage

La storia senza fine di Avastin e Lucentis, Soi denuncia: “Malati ancora senza farmaci”

RIFday (Comunicati Stampa) (Registrazione) - ‎14 hours ago‎
Roma, 9 febbraio – Si riapre il fronte delle polemiche su Avastin e Lucentis, farmaci entrambi impiegati (anche il primo, che è in realtà un antitumorale) nella terapia delle maculopatie degenerative. E il problema è sempre quello che ormai rimbalza ...

معلومات عن دواء افاستين Avastin وفيما يستخدم هذا الدواء

شبكة الرادار الاخبارية (بيان صحفي) - ‎Feb 7, 2016‎
تحتوي حقن أفاستين على العنصر النشط وبيفاسيزوماب ، يتم استخدامها لعلاج سرطان الأمعاء والمستقيم (سرطان القولون والمستقيم) وسرطانات الثدي التي انتشرت إلى أجزاء أخرى من الجسم . فإنه يمكن أيضا أن تستخدم لعلاج سرطان الرئة المتقدم ، وتقدم سرطان الكلى.

After a big 2015, Regeneron predicts slowing 2016 sales for launch superstar Eylea

FiercePharma - ‎7 hours ago‎
Plus, Eylea's market share is still ahead of its competitors'; in patients with diabetic macular edema, its slice of the pie is roughly double that of Roche's ($RHHBY) Lucentis and cancer med Avastin, which is frequently used off-label in the eye. And ...

Speaker delivers DRCR.net update at Angiogenesis meeting

Healio - ‎Feb 8, 2016‎
Protocol T, published in October 2015, compared the safety and efficacy of intravitreal Eylea (aflibercept, Regeneron), Avastin (bevacizumab, Genentech) and ranibizumab to treat central-involved DME in eyes with visual acuity of 20/32 to 20/320. All ...
See realtime coverage

New Therapy Shows Early Promise, Continues to Progress in Triple-Negative Breast Cancer

Curetoday.com - ‎Feb 8, 2016‎
... cyclophosphamide (93 percent), doxorubicin (83 percent), carboplatin (57 percent), gemcitabine (50 percent), capecitabine (43 percent), Halaven (eribulin; 38 percent), cisplatin (25 percent), vinorelbine (17 percent), and Avastin (bevacizumab; 13 ...

Crabby Joe's hosting Lee's Fundraiser

Bradford Times - ‎Jan 28, 2016‎
Unfortunately, Avastin is just the latest in “second generation” drug treatments that OHIP does not fund - leaving patients, already struggling with life-threatening disease, to struggle with the financial burden.

Drug meant for cancer, not eyes | Varanasi NYOOOZ

NYOOOZ - ‎Feb 3, 2016‎
It is not a multi-dose preparation because it does not contain preservatives and is not designed to be injected in the eye, said a statement of Roche Pharma India, the manufacturer of Avastin (Bevacizumab) which allegedly affected eyesight of seven ...

Will Amgen, Inc and Other Companies' Biosimilar Affect the Therapeutic Market?

Business Finance News - ‎5 hours ago‎
The patent expiration of several established drugs such as Humira patent expires in 2016, Rituxan patent expires in 2018, Lantus patent has already expired last year, as well as Avastin and Herceptin's patent will expire in 2019 will aid in steep ...

Racial, treatment-related factors may influence bevacizumab efficacy in advanced cervical cancer

Healio - ‎Feb 7, 2016‎
Use of Moore criteria may identify patients with advanced cervical cancer who may not benefit from treatment with bevacizumab, according to results of a study conducted by the Gynecologic Oncology Group.
See realtime coverage

BHU doctor's injection 'makes' 7 blind; FIR filed

ETHealthWorld.com - ‎Jan 31, 2016‎
Maurya informed TOI, "As each vial of 'Avastin,' the only medicine for the treatment of this disease, costs up to Rs 23,500 we ensure that it is purchased by a group of patients.
See realtime coverage

Roche looks ahead to immuno-oncology, MS to back up big-selling cancer meds

FiercePharma - ‎Jan 28, 2016‎
Roche ($RHHBY) counts on its tried-and-true cancer drugs Rituxan, Avastin and Herceptin to bring home the bacon, and the meds did not disappoint in 2015.

ImmunoGen/Merck Collaborate for Ovarian Cancer Study

Yahoo News - ‎Feb 5, 2016‎
Mirvetuximab soravtansine is currently being evaluated in the phase Ib/II FORWARD II study in combination with anticancer agents including Doxil (doxorubicin), Avastin (bevacizumab) and Paraplatin (carboplatin). The mirvetuximab soravtansine-Keytruda ...

Regeneron: It's the Eylea Outlook That Matters

Barron's (blog) - ‎Feb 8, 2016‎
... ~$750 M. In addition, Roche said on their 4Q call that they “expect a moderate decline” in Lucentis in 2016, which would likely bode well for Eylea, yet Roche also believes that Eylea, Lucentis, and Avastin are “kind of positioning out relative to ...
See realtime coverage

Immunotherapy Is ASCO's Advance of the Year

Medscape - ‎Feb 4, 2016‎
In the trial, the vaccine was used together with bevacizumab (Avastin), which improved median survival to 12 months compared with 8.8 months in the bevacizumab-alone group.

Why Ophthotech Corporation Shares Tumbled 31% in January

Motley Fool - ‎Feb 6, 2016‎
Currently, Novartis' (NYSE:NVS) Lucentis, Regeneron's (NASDAQ:REGN) Eylea, and off-label use of Roche's (NASDAQOTH:RHHBY) Avastin are used to treat wet AMD in a market valued at $7.1 billion annually, and growing. In phase 2 trials, combining ...
 -